Goldman Sachs’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-265,635
| Closed | -$2.44M | – | 6738 |
|
|
2021
Q2 | $2.44M | Buy |
265,635
+75,197
| +39% | +$437K | ﹤0.01% | 4025 |
|
|
2021
Q1 | $947K | Buy |
190,438
+56,249
| +42% | +$272K | ﹤0.01% | 4658 |
|
|
2020
Q4 | $578K | Sell |
134,189
-4,948
| -4% | -$20.1K | ﹤0.01% | 4520 |
|
|
2020
Q3 | $597K | Buy |
139,137
+33,267
| +31% | +$139K | ﹤0.01% | 4383 |
|
|
2020
Q2 | $476K | Buy |
105,870
+64,603
| +157% | +$289K | ﹤0.01% | 4402 |
|
|
2020
Q1 | $165K | Buy |
41,267
+13,133
| +47% | +$112K | ﹤0.01% | 4767 |
|
|
2019
Q4 | $238K | Sell |
28,134
-116,005
| -80% | -$905K | ﹤0.01% | 4837 |
|
|
2019
Q3 | $988K | Buy |
144,139
+130,280
| +940% | +$955K | ﹤0.01% | 4042 |
|
|
2019
Q2 | $115K | Buy |
13,859
+1,533
| +12% | +$13.2K | ﹤0.01% | 4901 |
|
|
2019
Q1 | $113K | Sell |
12,326
-20,508
| -62% | -$208K | ﹤0.01% | 4912 |
|
|
2018
Q4 | $360K | Sell |
32,834
-18,424
| -36% | -$232K | ﹤0.01% | 4550 |
|
|
2018
Q3 | $715K | Buy |
51,258
+37,267
| +266% | +$504K | ﹤0.01% | 4229 |
|
|
2018
Q2 | $149K | Sell |
13,991
-501
| -3% | -$4.89K | ﹤0.01% | 5093 |
|
|
2018
Q1 | $125K | Buy |
+14,492
| New | +$127K | ﹤0.01% | 5199 |
|
|
2017
Q4 | – | Sell |
-48,932
| Closed | -$384K | – | 6787 |
|
|
2017
Q3 | $384K | Buy |
48,932
+33,422
| +215% | +$251K | ﹤0.01% | 5290 |
|
|
2017
Q2 | $133K | Sell |
15,510
-6,826
| -31% | -$49K | ﹤0.01% | 6006 |
|
|
2017
Q1 | $157K | Buy |
22,336
+4,954
| +29% | +$31K | ﹤0.01% | 5852 |
|
|
2016
Q4 | $74K | Sell |
17,382
-6,271
| -27% | -$30.3K | ﹤0.01% | 6272 |
|
|
2016
Q3 | $118K | Sell |
23,653
-4,719
| -17% | -$19.9K | ﹤0.01% | 6147 |
|
|
2016
Q2 | $100K | Buy |
28,372
+3,275
| +13% | +$12K | ﹤0.01% | 6127 |
|
|
2016
Q1 | $87K | Buy |
25,097
+64
| +0.3% | +$226 | ﹤0.01% | 6143 |
|
|
2015
Q4 | $85K | Sell |
25,033
-1,368
| -5% | -$6.34K | ﹤0.01% | 6269 |
|
|
2015
Q3 | $137K | Sell |
26,401
-58,529
| -69% | -$361K | ﹤0.01% | 6273 |
|
|
2015
Q2 | $579K | Buy |
+84,930
| New | +$602K | ﹤0.01% | 5038 |
|
|
2014
Q3 | – | Sell |
-14,063
| Closed | -$262K | – | 7327 |
|
|
2014
Q2 | $262K | Buy |
+14,063
| New | +$239K | ﹤0.01% | 5992 |
|
Other funds holding KIN
Goldman Sachs's KIN Position: Q3 2021 in Review
Goldman Sachs sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 265,635 shares — an estimated $2.44M sold.
Goldman Sachs first reported a position in KIN in Q2 2014 and held it in 25 quarters. The position peaked at $2.44M in Q2 2021. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- Goldman Sachs reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Goldman Sachs sold 265,635 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $2.44M.
- Goldman Sachs first reported a position in Kindred Biosciences, Inc. in Q2 2014 and held it in 25 quarters.
- Goldman Sachs's Kindred Biosciences, Inc. position peaked at $2.44M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.